Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, aged 18 to 75 years
- Pathologically confirmed metastatic (spread beyond breast) or locally advanced unresectable breast cancer
- Cancer is hormone-receptor-positive and HER2-positive
- No cancer progression after 4–8 cycles of first-line chemotherapy or targeted therapy (stable disease, partial response, or complete response)
- ECOG performance status 0–1 (able to carry out daily activities with minimal assistance)
- No symptomatic brain metastases or extensive leptomeningeal disease (cancer in brain fluid)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
This trial tests a drug called Dalpiciclib for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). It aims to see if it can help stop the cancer from growing.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
Hear when a new Advanced/Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.